Samuele Takeshita: Future Perspectives on Gene Therapy Access Through Hemophilia and Sickle Cell Disease
Samuele Takeshita, Head of Sales and Business Development at ELIXI International, shared a post on LinkedIn:
“A highly suggested reading to capture both the scientific and practical aspects of gene therapy access in hemophilia and sickle cell disease (SCD).
It explains how gene therapy science differs between viral vector‑based and ex vivo cell‑based approaches and their clinical implications.
In hemophilia, adeno‑associated viral (AAV) vectors deliver functional factor VIII or IX genes but can trigger inflammatory hepatotoxicity, requiring corticosteroid management.
In SCD, autologous hematopoietic stem cells are modified ex vivo (via lentiviral or CRISPR techniques) and reinfused after conditioning, providing durable functional hemoglobin but high acute toxicity risk.
Both approaches demonstrate durable efficacy, though long‑term safety data remain limited.”
Stay updated with Hemostasis Today.
-
Mar 31, 2026, 14:20Dear Thamasucharit: Why Hemostasis Testing and Bleeding Disorder Awareness Matter More Than You Think
-
Mar 31, 2026, 13:49New Researchs at ACC26 on Everyday Clinical Decisions – The Lancet Group
-
Mar 31, 2026, 12:58Akshat Jain: The Invisible Struggles of Living with Von Willebrand Disease
-
Mar 31, 2026, 12:50Emmanuele Kouvousis: DOAC Dose Adjustments for Older Patients
-
Mar 31, 2026, 12:34How Clinicians Prioritize Factors in Red Blood Cell Transfusions While Following Guidelines – AABB
-
Mar 31, 2026, 12:13Tareq Abadl: What if a Hospital Bacterium Can Survive on Dry Surfaces for Days to Weeks?
-
Mar 31, 2026, 11:35Lale Tokgözoğlu: Significant CV Benefit of Lowering LDL to 44 mg/dL in Diabetes
-
Mar 31, 2026, 09:08Shamee Shastry: Sharing Perspectives on Therapeutic Apheresis at AIIMS CME
-
Mar 31, 2026, 08:57Heghine Khachatryan: Heavy Menstrual Bleeding is Not ‘Normal’ – It is Often Missed Pathology